✦ LIBER ✦

CPMP ‘Note for Guidance’ on bioavailability and bioequivalence

✍ Scribed by Jóse A. Guimarães Morais

Book ID: 105731530
Publisher: Springer-Verlag
Year: 2000
Tongue: English
Weight: 204 KB
Volume: 25
Category: Article
ISSN: 0378-7966
DOI: 10.1007/bf03190064

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Japanese guidance on bioavailability and

Japanese guidance on bioavailability and bioequivalence

✍ Nobuo Aoyagi 📂 Article 📅 2000 🏛 Springer-Verlag 🌐 English ⚖ 474 KB

Guidances related to bioavailability and

✍ Gertrud Ahr; Barbara Voith; Jochen Kuhlmann 📂 Article 📅 2000 🏛 Springer-Verlag 🌐 English ⚖ 344 KB

Bioavailability and Bioequivalence: Focu

Bioavailability and Bioequivalence: Focus on Physiological Factors and Variability

✍ Vangelis Karalis; Panos Macheras; Achiel Van Peer; Vinod P. Shah 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 138 KB

Neue “Note for Guidance on the Pharmacod

Neue “Note for Guidance on the Pharmacodynamic Section of the SPC for Anti-Bacterial Medicinal Products, CPMP/EWP/520/96”Regulatorische Aspekte

✍ G. Steinheider 📂 Article 📅 1999 🏛 Springer 🌐 German ⚖ 61 KB

Using Partial Area for Evaluation of Bio

Using Partial Area for Evaluation of Bioavailability and Bioequivalence

✍ Mei-Ling Chen; Barbara Davit; Robert Lionberger; Zakaria Wahba; Hae-Young Ahn; L 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 315 KB

Some statistical considerations on the F

Some statistical considerations on the FDA draft guidance for individual bioequivalence

✍ Francis C. Hsuan 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

In December of 1997, the FDA proposed a draft guidance for future in vivo bioequivalence studies. The guidance suggested speciÿc criteria for new drug sponsors to show individual bioequivalence (IBE). The criteria use a mixed-scaling aggregate strategy. It has been generally accepted that, under som